维泊妥珠单抗治疗B细胞淋巴瘤临床应用指导原则  

Guideline principles for clinical application of polatuzumab vedotin in treatment of B-cell lymphoma

作　　者：中国临床肿瘤学会(CSCO)淋巴瘤专家委员会 马军[2] Lymphoma Expert Committee of Chinese Society of Clinical Oncology(CSCO);Ma Jun

机构地区：[1]不详 [2]哈尔滨血液病肿瘤研究所,哈尔滨150010

出　　处：《白血病．淋巴瘤》2023年第6期321-328,共8页Journal of Leukemia & Lymphoma

摘　　要：维泊妥珠单抗是一种靶向CD79b的新型抗体药物偶联物。维泊妥珠单抗联合化疗用于初治或复发难治弥漫大B细胞淋巴瘤(DLBCL), 可有效降低疾病进展或死亡风险, 患者获益显著。维泊妥珠单抗已在全球80多个国家和地区获批上市, 在我国也获得加速批准, 用于治疗DLBCL。专家组成员结合国内外相关研究和临床实践, 制定了维泊妥珠单抗治疗B细胞淋巴瘤临床应用指导原则, 旨在为我国临床医师规范、合理用药提供参考。Polatuzumab vedotin is a novel CD79b-targeted antibody-drug conjugate.Polatuzumab vedotin combined with chemotherapy can effectively reduce the disease progression and death risk as well as bring significant clinical benefits for patients with previously untreated or relapsed/refractory diffuse large B-cell lymphoma(DLBCL).Polatuzumab vedotin has been approved for marketing in more than 80 countries and regions worldwide,and has been granted accelerated approval in China for DLBCL.By collecting and analyzing the published data from clinical trials or routine practices domestically or internationally,the expert panel formulated this consensus to guide clinical medication of polatuzumab vedotin and to provide the reference for its normative use by Chinese clinicians.

关 键 词：淋巴瘤 B细胞 维泊妥珠单抗 抗体药物偶联物 

分 类 号：R733.1[医药卫生—肿瘤]